Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease

    Trinh Hermanns‐Lê, Enzo Berardesca, Gérald Pierard, Marianne Lesuisse, C Piérard-Franchimont
    Image of study
    TLDR Ustekinumab might work for severe psoriasis, but more research is needed to be sure.
    The 2012 document reviews the use of ustekinumab, a monoclonal antibody, for treating challenging forms of regional psoriasis, including palmoplantar, nail, and scalp psoriasis. It indicates that while there are some reports of ustekinumab's potential efficacy, the number of patients treated is too limited to draw definitive conclusions, and further research is needed to assess its cost-effectiveness and risk-benefit ratio. The document also discusses the unknown causes of regional psoriasis, the importance of individualized treatment plans, and the potential effectiveness of ustekinumab in both biologic-naive patients and those who have not responded to other biotherapies. It highlights the need to consider the psychological impact of psoriasis and the challenges of comparing drugs due to the personalized nature of treatment.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 202 results